Book of abstracts by unknown
22-23 October 2018 LJUBLJANA (SI)
ESSO Course on Electrochemo-
therapy of Cutaneous and Deep 
Seated Tumours
In partnership with Institute of Oncology Ljubljana and University 
Medical Center Ljubljana
22-23 October 2018 LJUBLJANA (SI)
ESSO Course on Electrochemo-
therapy of Cutaneous and Deep 
Seated Tumours
In partnership with Institute of Oncology Ljubljana and University 
Medical Center Ljubljana
Organized by:  European Society of Surgical Oncology (Brussels, Belgium) in partnership 
 with Institute of Oncology Ljubljana (Ljubljana, Slovenia) and  
 University Medical Center (Ljubljana, Slovenia)
Chairs of the course: Ibrahim Edhemovic, Institute of Oncology Ljubljana, Ljubljana, Slovenia 
 Gregor Sersa, Institute of Oncology Ljubljana, Ljubljana, Slovenia 
Faculty members: Giulia Bertino, Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy 
 Nina Boc, Institute of Oncology Ljubljana, Ljubljana, SIovenia 
 Erik Brecelj, Institute of Oncology Ljubljana, Ljubljana, Slovenia 
 Luca Campana, Veneto Institute of Oncology IRCCS and University of 
 Padova, Padova, Italy 
 Maja Cemazar, Institute of Oncology Ljubljana, Ljubljana, Slovenia 
 Mihajlo Djokic, University Clinical Center Ljubljana, Ljubljana, Slovenia 
 Julie Gehl, University of Copenhagen, Copenhagen, Denmark 
 Ales Groselj, University Clinical Center Ljubljana, Ljubljana, Slovenia 
 Bor Kos, Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, 
 Slovenia 
 Damijan Miklavcic, Faculty of Electrical Engineering, University of Ljubljana, 
 Ljubljana, Slovenia 
 Marko Snoj, Institute of Oncology Ljubljana, Ljubljana, Slovenia 
 Blaz Trotovsek, University Clinical Center Ljubljana, Ljubjana, Slovenia
BOOK OF ABSTRACTS 
ESSO Course on Electrochemotherapy of Cutaneous and Deep Seated Tumors
Editors:  Gregor Sersa, Ibrahim Edhemovic, Simona Kranjc Brezar, Masa Bosnjak, 
 Ursa Lampreht Tratar
Reviewed by: Eldar M. Gadzijev
Technical Editor: Simona Kranjc Brezar
Design:  Simona Kranjc Brezar
Printed by:  Fota-Cop d.o.o., Ljubljana, Slovenia
Issued by:                       Institute of Oncology Ljubljana, Ljubljana, Slovenia
Edition:                           1st edition, 80 copies, free copy
Web page:                      https://www.essoweb.org/
  CIP - Kataložni zapis o publikaciji
  Narodna in univerzitetna knjižnica, Ljubljana
  616-006-085.84:615.277.3(082)
  ESSO Course on Electrochemotherapy of Cutaneous and Deep Seated 
Tumors (2018 ; Ljubljana) 
           Book of abstracts / ESSO Course on Electrochemotherapy of 
Cutaneous and Deep Seated Tumors, 22-23 October 2018 ; organized 
by European Society of Surgical Oncology (Brussels, Belgium) in 
partnership with Institute of Oncology Ljubljana (Ljubljana, Slovenia) 
and University Medical Center (Ljubljana, Slovenia) ; [editors Gregor 
Sersa ... et al.]. - 1st ed. - Ljubljana : Institute of Oncology, 2018 
 ISBN 978-961-7029-09-3  
                      1. Serša, Gregor 2. European Society of Surgical Oncology 3. Onkološki inštitut (Ljubljana) 
4. Univerzitetni klinični center Ljubljana 
  296993792
1
ESSO Course on Electrochemotherapy 




Organized by European Society of Surgical Oncology (Brussels, Belgium) in 
partnership with Institute of Oncology Ljubljana (Ljubljana, Slovenia) and  
University Medical Center Ljubljana (Ljubljana, Slovenia)
Chairs of the course: Ibrahim Edhemovic, Institute of Oncology Ljubljana    











 Monday 22nd October
9:00 - 9:10 Welcome
 Theoretical Backgrounds
09:10 - 9:30 Principles of electric field application in electrochemotherapy 
Damijan Miklavcic (Ljubljana, Slovenia)
09:30 - 9:50 Basics and mechanisms of electrochemotherapy 
Maja Cemazar & Gregor Sersa (Ljubljana, Slovenia)
09:50 - 10:10 Overview of clinical applications in cutaneous tumors 
Marko Snoj (Ljubljana, Slovenia)
10:10 - 10:30 Coffee Break 
10:30 - 10:50 How to treat cutaneous tumors, new SOP and side effects 
Julie Gehl (Copenhagen, Denmark)
10:50 - 11:10 Pharmacology of bleomycin, implications in lowering the dose 
Ales Groselj (Ljubljana, Slovenia)
11:10 - 11:30 Electrochemotherapy of melanoma metastases 
Luca Campana (Padova, Italy)
11:30 - 11:50 Electrochemotherapy of head and neck cancer 
Giulia Bertino (Pavia, Italy)
11:50 - 13:00 Lunch
 Live Sesions
13:00 - 16:00 Treatment of skin head and neck tumors 
Ales Groselj & Marko Snoj (Ljubljana, Slovenia)
 Case discussion session
16:00 - 18:00 Skin tumors 
Moderators: Julie Gehl (Copenhagen, Denmark), Luca Campana 
(Padova, Italy), Giulia Bertino (Pavia, Italy), Ales Groselj (Ljubljana, 




 Tuesday 23rd October
 Theoretical Backgrounds
9:00 - 9:20 Overview of ECT application in deep seated tumors 
Ibrahim Edhemovic (Ljubljana, Slovenia)
09:20 - 9:40 Treatment planning 
Bor Kos (Ljubljana, Slovenia)
09:40 - 10:00 Treatment verification 
Nina Boc (Ljubljana, Slovenia)
10:00 - 10:20 Experience in treatment of colorectal liver metastases 
Ibrahim Edhemovic & Erik Brecelj (Ljubljana, Slovenia)
10:20 - 10:40 Experience in treatment of hepatocellular carcinoma 
Blaz Trotovsek & Mihajlo Djokic (Ljubljana, Slovenia)
10:40 - 11:10 Coffee break
 Live Sessions
11:10 - 14:00 Treatment of liver tumors 
Ibrahim Edhemovic (Ljubljana, Slovenia), Erik Brecelj (Ljubljana, 
Slovenia), Blaz Trotovsek (Ljubljana, Slovenia), Mihajlo Djokic 
(Ljubljana, Slovenia)
 Case Discussion Session
14:00 - 15:00 Liver tumors 
Moderators: Ibrahim Edhemovic (Ljubljana, Slovenia), Erik Brecelj 
(Ljubljana, Slovenia), Blaz Trotovsek (Ljubljana, Slovenia), Mihajlo 
Djokic (Ljubljana, Slovenia)





1 Principles of electric field application in electrochemotherapy 
Damijan Miklavcic (Ljubljana, Slovenia) 8
2 Basics and mechanisms of electrochemotherapy 
Maja Cemazar, Gregor Sersa (Ljubljana, Slovenia) 10
3 Overview of clinical applications in cutaneous tumors 
Marko Snoj (Ljubljana, Slovenia) 18
4 How to treat cutaneous tumors, new SOP and side effects 
Julie Gehl (Copenhagen, Denmark) 19
5 Pharmacology of bleomycin, implications in lowering the dose 
Ales Groselj (Ljubljana, Slovenia) 21
6 Electrochemotherapy of melanoma metastases 
Luca Campana (Padova, Italy) 22
7 Electrochemotherapy of head and neck cancer 
Giulia Bertino (Pavia, Italy) 23
8 Overview of ECT application in deep seated tumors 
Ibrahim Edhemovic (Ljubljana, Slovenia) 28
9 Treatment planning for electroporation-based therapies 
Bor Kos (Ljubljana, Slovenia) 29
10 Treatment verification 
Nina Boc (Ljubljana, Slovenia) 30
11 Experience in treatment of colorectal liver metastases 
Erik Brecelj, Ibrahim Edhemovic (Ljubljana, Slovenia) 32
12 Experience in treatment of hepatocellular carcinoma 
Blaz Trotovsek, Mihajlo Djokic (Ljubljana, Slovenia) 33
8
PRINCIPLES OF ELECTRIC FIELD APPLICATION IN 
ELECTROCHEMOTHERAPY
Damijan Miklavcic 
University of Ljubljana, Faculty of Electrical Engineering, Trzaska cesta 25, SI-1000 Ljubljana, 
Slovenia
E-mail: damijan.miklavcic@fe.uni-lj.si
Electrochemotherpay is a combined 
treatment using electroporation to 
enhance transmembrane transport of 
cytotoxic drugs, which have intracellular 
target, and for which plasma membrane 
represents a barrier. It is therefore 
important that two conditions be met: i) 
the drug is present in the tumor in sufficient 
concentration, and ii) the whole tumor 
mass is exposed to sufficiently high 
electric field (1, 2). The drug is injected 
either systemically, e.g. intravenously or 
intratumorally, while the exposure of cells 
in the tumor to electric is achieved by 
delivering electric pulses by selecting 
adequate electrodes and positioning them 
correctly with respect to the tumor (2, 3).
The membrane of the cell when 
exposed to sufficiently high electric field 
will undergo electroporation that will 
transiently increase its permeability thus 
allowing increased inflow of molecules 
that otherwise lack or have hindered 
transmembrane transport (4). Electric field 
distribution depends on the geometry 
and position of the electrodes relative to 
the tumor (5, 6). For treating metastasis/
tumors in the skin selecting appropriate 
choice of the electrode and placing it 
seem not to be difficult (1), however when 
treating deep seated tumors and/or large 
tumors pretreatment planning (similar 
to radiotherapy) and image guidance 
assistance is necessary (7-8). Validated 
numerical models are essential in achieving 
best results with electrochemotherapy 
and developing new approaches (9).
Acknowledgements
This work was in part supported by 
Slovenian Reasearch agency and 
conductaed in the scope of LEA EBAM. 
References
1. Miklavčič D, Čorović S, Pucihar G, Pavšelj 
N. Importance of tumour coverage by 
sufficiently high local electric field for 
effective electrochemotherapy. Eur J Cancer 
2006;Suppl 4: 45-51. 
2. Miklavčič D, Mali B, Kos B, Heller R, Serša G. 
Electrochemotherapy: from the drawing board 
into medical practice. Biomed Eng Online 
2004;13: 29. 
3. Miklavčič D, Snoj M, Županič A, Kos B, 
Čemažar M, Kropivnik M, Bračko M, Pečnik 
T, Gadžijev E, Serša G. Towards treatment 
planning and treatment of deep-seated solid 
tumors by electrochemotherapy. Biomed Eng 
Online 2010;9: 10. 
4. Rems L, Miklavčič D. Tutorial: Electroporation 
of cells in complex materials and tissue. J 
Appl Phys 2016;119: 201101. 
5. Kranjc M, Markelc B, Bajd F, Čemažar M, Serša 
I, Blagus T, Miklavčič D. In situ monitoring 
of electric field distribution in mouse tumor 
during electroporation. Radiology 2015;274: 
115-123. 
6. Miklavčič D, Beravs K, Šemrov D, Čemažar 
M, Demšar F, Serša G. The importance of 
electric field distribution for effective in vivo 
electroporation of tissues. Biophys J 1998;74: 
2152-2158.
7. Pavliha D, Kos B, Županič A, Marčan M, 
Serša G, Miklavčič D. Patient-specific 
treatment planning of electrochemotherapy: 
Procedure design and possible pitfalls. 
Bioelectrochemistry 2012;87: 265-273. 
8. Marčan M, Pavliha D, Kos B, Forjanič T, 
Miklavčič D. Web-based tool for visualization 
of electric field distribution in deep-
seated body structures and planning of 
9
electroporation-based treatments. Biomed 
Eng Online 2015;14(Suppl. 3): S4. 
9. Cindrič H, Kos B, Tedesco G, 
Cadossi M, Gasbarrini A, Miklavčič D. 
Electrochemotherapy of spinal metastases 
using transpedicular approach – A numerical 
feasibility study. Technol Cancer Res Treat 
2018;17: 1-13.
10
BASIC MECHANISMS OF ELECTROCHEMOTHERAPY
Maja Cemazar and Gregor Sersa
Institute of Oncology Ljubljana, Department of Experimental Oncology, Zaloska cesta 2,        
SI-1000 Ljubljana, Slovenia
E-mail: mcemazar@onko-i.si; gsersa@onko-i.si
Abstract: Electrochemotherapy consists of chemotherapy followed by local application of 
electric pulses to the tumor to increase drug delivery into cells in tumors. Drug uptake can 
be increased by electroporation only for drugs having impeded transport through the plasma 
membrane. Among many drugs which have been tested so far, only cisplatin and bleomycin have 
found their way from preclinical testing to clinical trials. In vitro studies demonstrated a several-
fold increase of their cytotoxicity by electroporation of cells. In vivo, electroporation of tumors 
after local or systemic administration of either of the drugs i.e. electrochemotherapy, proved 
to be an effective antitumor treatment. Electrochemotherapy studies using either bleomycin 
or cisplatin in several tumor models elaborated treatment parameters for effective local tumor 
control. In veterinary medicine, electrochemotherapy proved to be effective in primary tumors 
in cats, dogs and horses. In clinical studies, electrochemotherapy was performed on accessible 
tumor nodules of different malignancies in progressive disease. All clinical studies provided 
evidence that electrochemotherapy is an effective treatment for local tumor control in patients 
with different types of cancer.
 
INTRODUCTION
Treatments for cancer may be divided 
into different categories based on their 
goals and mode of action. Very often, 
the different types of treatment are used 
in combination, either simultaneously or 
sequentially. In general, cancer treatment 
includes three major treatment modalities: 
surgery and radiation, which are local 
treatment modalities and chemotherapy, 
which is a systemic treatment modality.
Chemotherapy, a systemic treatment 
modality for cancer, is effective for 
drugs which readily cross the plasma 
membrane and are cytotoxic once they 
reach their intracellular targets. However, 
among the chemotherapeutic drugs 
which are very cytotoxic, there is some 
having hampered transport through the 
plasma membrane. These drugs are good 
candidates for electrochemotherapy. 
Electrochemotherapy is a local treatment 
combining chemotherapy and application 
of electric pulses to the tumor. In 
electrochemotherapy, the optimal anti-
tumor effectiveness is achieved when 
electric pulses are given at the time of 
the highest extracellular concentration of 
the hydrophilic chemotherapeutic drug, 
thereby increasing its transport through 




Electroporation proved to be effective in 
facilitating transport of different molecules 
across the plasma membrane for different 
biochemical and pharmacological studies. 
However, when using chemotherapeutic 
drugs, this facilitated transport increases 
intracellular drug accumulation with 
the aim to increase their cytotoxicity. 
Since electroporation can facilitate drug 
transport through the cell membrane only 
for molecules which are poorly permeant 
or non-permeant, suitable candidates 
for electrochemotherapy are limited to 
those drugs that are hydrophilic and/or 
lack a transport system in the membrane. 
Several chemotherapeutic drugs were 
tested in vitro for potential application 
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in combination with electroporation of 
cells. Among the tested drugs, only two 
were identified as potential candidates for 
electrochemotherapy of cancer patients. 
The first is bleomycin, which is hydrophilic 
and has very restricted transport through 
the cell membrane, but its cytotoxicity can 
be potentiated up to several 1000 times 
by electroporation of cells. A few hundred 
internalized molecules of bleomycin are 
sufficient to kill the cell. The second is 
cisplatin, whose transport through the cell 
membrane is also hampered. Early studies 
suggested that cisplatin is transported 
through the plasma membrane mainly 
by passive diffusion, while recent studies 
have demonstrated that transporters 
controlling intracellular copper 
homeostasis are significantly involved in 
influx (Ctr1) and efflux (ATP7A and ATP7B) 
of the cisplatin (5). Electroporation of the 
plasma membrane enables greater flux 
and accumulation of the drug in the cells, 
which results in an increase of cisplatin 
cytotoxicity by up to 80-fold (1-4). This 
promising preclinical data obtained in 
vitro on a number of different cell lines 
has paved the way for testing these two 
drugs in electrochemotherapy in vivo on 
different tumor models.
In vivo studies
Bleomycin and cisplatin were tested 
in an electrochemotherapy protocol in 
animal models in vivo (Figure 1). Extensive 
studies in different animal models 
with different types of tumors, either 
transplantable or spontaneous, were 
performed. The antitumor effectiveness of 
electrochemotherapy was demonstrated 
on tumors in mice, rats, hamsters, cats, 
dogs, horses and rabbits. Tumors treated 
by electrochemotherapy were either 
subcutaneous or located in muscle, brain 
or liver, being sarcomas, carcinomas, 
gliomas or malignant melanoma (1-4,6).
In these studies, different factors 
controlling antitumor effectiveness were 
determined:
•	 The	 drugs	 can	 be	 given	 by	 different	
routes of administration, they can 
be injected either intravenously or 
intratumorally. The prerequisite is that, at 
the time of application of electric pulses 
to the tumor, a sufficient amount of 
drug is present in the tumor. Therefore, 
after intravenous drug administration 
into small laboratory animals ( for 
example 4 mg/kg of cisplatin or 0.5 
mg/kg bleomycin), only a few minutes 
interval is needed to reach the maximal 
drug concentration in the tumors. After 
intratumoral administration, this interval 
is even shorter and the application 
of electric pulses has to follow the 
administration of the drug as soon as 
possible (within a minute) (1-4).
•	 Good	 antitumor	 effectiveness	
may be achieved by good tissue 
electroporation. Electroporation of the 
plasma membrane is obtained if the cell 
is exposed to a sufficiently high electric 
field. This depends on the electric 
field distribution in the tissue which is 
controlled by the electrode geometry 
Figure 1. Protocol of electrochemotherapy of 
experimental tumors presented schematically. 
The drug is injected either intravenously or 
intratumorally at doses which do not usually exert 
an antitumor effect. After an interval which allows 
sufficient drug accumulation in the tumors, electric 
pulses are applied to the tumor either by plate or 
needle electrodes. The electrodes are placed in 
such a way that the whole tumor is encompassed 
between the electrodes, providing good electric 
field distribution in the tumors for optimal 
electroporation of cells in the tumors.
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and tissue composition. The electric 
field distribution in the tissue and cell 
electroporation can be improved by 
rotating the electric field. Surface 
tumours can be effectively treated by 
plate electrodes, whereas appropriate 
electric field distribution in the deeper 
parts of the tumour is assured by using 
needle electrodes (7-9).
•	 The	 antitumor	 effectiveness	 depends	
on the amplitude, number, frequency 
and duration of the electric pulses 
applied. Several studies in which 
parallel plate electrodes were used for 
surface tumors showed that amplitude 
over distance ratio above 1000 V/cm 
is needed for tumor electroporation, 
and that above 1500 V/cm, irreversible 
changes in the normal tissues adjacent 
to the tumor occur. So, the window for 
effective and safe electrochemotherapy 
is between 1000-1500 V/cm. In most 
studies, the amplitude over distance 
ratio of 1300 V/cm induced good 
antitumor effectiveness without sub-
optimal electroporation of the tissue or 
damage to the tissue due to irreversible 
cell permeabilisation (8). For other 
types of electrodes, the electric 
field distribution and thus, also the 
necessary amplitude of electric pulses, 
need to be determined by numerical 
calculations. Repetition frequencies of 
the pulses for electrochemotherapy are 
either 1 Hz or 5 kHz with equal effect 
if the concentration of drug present in 
the tumor is high enough. The minimal 
number of pulses used is 4; most 
studies use 8 electric pulses of 100 μs 
(1,4,8,10-12).
All the experiments conducted in vivo 
in animals provided sufficient data to 
demonstrate that electrochemotherapy 
with either bleomycin or cisplatin is 
effective in the treatment of solid tumors, 
using drug concentrations which have 
no or minimal antitumor effect without 
application of electric pulses. A single 
treatment by electrochemotherapy already 
induces partial or complete regression of 
tumors, whereas treatment with bleomycin 
or cisplatin alone or application of electric 
pulses alone has no or minimal antitumor 
effect (Figure 2).
Mechanisms of action
The principal mechanism of 
electrochemotherapy is electroporation 
of cells in the tumors, which increases the 
drug effectiveness by enabling the drug 
to reach the intracellular target. This was 
demonstrated in studies which measured 
the intratumoral drug accumulation 
and the amount of drug bound to DNA. 
Basically, the amounts of bleomycin and 
cisplatin in the electroporated tumours 
were up to 2-4 fold higher than in those 
without application of electric pulses (1-4).
Besides membrane electroporation, 
which facilitates drug transport and its 
accumulation in the cell, other mechanisms 
that are involved in the antitumor 
effectiveness of electrochemotherapy 
were described. The application of electric 
pulses to tissues induces a transient, but 
reversible reduction of blood flow (13,14). 
Figure 2. Example of good antitumor effectiveness 
in SA-1 tumors after electrochemotherapy with 
cisplatin. Cisplatin was given intravenously (4 mg/
kg), 3 min thereafter 8 electric pulses were applied 
to the tumor with plate electrodes. Electric pulses 
were applied in two directions; 4 pulses in one and 
the other 4 in the perpendicular direction. Eight days 
after the treatment good antitumor effectiveness 
of electrochemotherapy with cisplatin is evident, 
compared to the single treatments with cisplatin 
or electric pulses.
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Restoration of the blood flow in normal 
tissue is much faster than that in tumors 
(14,15). The vascular lock in the tumor 
induces drug entrapment in the tissue, 
providing more time for the drug to act. 
The cytotoxic effect of electrochemotherapy 
is not limited only to tumor cells in the 
tumors. Electrochemotherapy also acts 
on stromal cells, including endothelial 
cells in the lining of tumor blood 
vessels, which undergo cell death (16). 
Consequently, by vascular-disrupting 
action of electrochemotherapy, a cascade 
of tumor cell death occurs due to long-
lasting hypoxia in the affected vessels. 
This represents yet another mechanism 
involved in the antitumor effectiveness 
of electrochemotherapy, i.e. a vascular-
disrupting effect (17-19). This vascular-
disrupting action of electrochemotherapy 
is important in clinical situations where 
haemorrhagic tumor nodules need to be 
treated (20).
A difference in the antitumor effectiveness 
of electrochemotherapy was observed 
between immunocompetent and 
immunodeficient experimental animals, 
indicating on involvement of the immune 
response in antitumor effectiveness (21). 
Due to massive tumor antigen shedding 
in organisms after electrochemotherapy, 
systemic immunity can be induced and 
also up-regulated by additional treatment 
with biological response modifiers like IL-
2, GM-CSF and TNF-α (22-24).
To sum up, the electrochemotherapy 
protocol was optimized in preclinical 
studies in vitro and in vivo, and basic 
mechanisms were elucidated. In addition 
to the electroporation of cells, vascular 
lock leading to drug entrapment in 
tumors, a vascular- disrupting effect and 
involvement of the immune response were 
also demonstrated. Based on all this data, 
electrochemotherapy with bleomycin and 
cisplatin was promptly evaluated in clinical 
trials and is now in routine use in human 
and veterinary oncology.
PERSPECTIVES
Knowledge about the mechanisms 
involved in the antitumor effectiveness 
of electrochemotherapy opened new 
possibilities for the application of electric 
pulses or electrochemotherapy in the 
treatment of cancer.
The chemotherapeutic drugs which 
increase effectiveness of radiation therapy 
are radiosensitizing drugs. These include 
bleomycin and cisplatin. Recently, some 
new drugs and chemicals were used 
in combination with electric pulses in 
preclinical studies, such as Mitomycin 
C, Ruthenium compounds and Calcium. 
The results of the studies in mice shown 
positive effects (25-27). Since drug delivery 
induced by electroporation is site-specific, 
it could be used for tumor-specific delivery 
of radiosensitizing drugs. By increased 
radiosensitizing drug delivery into tumors 
and not in the surrounding normal tissue, 
the therapeutic index of tumor irradiation 
is increased. In our studies, we combined 
electrochemotherapy with bleomycin 
or cisplatin with radiotherapy and 
demonstrated a good potentiation of the 
sarcoma tumor radiation response: 1.9-fold 
for electrochemotherapy with bleomycin 
and 1.6- fold for electrochemotherapy 
with cisplatin (28,29). The radiosensitizing 
effect of electrochemotherapy with 
cisplatin was also demonstrated in 
breast cancer and with bleomycin in a 
fractionated radiation regime which makes 
this treatment potentially available also in 
the clinic (30,31).
The application of electric pulses was 
shown to modulate tumor blood flow. 
Both reduced blood flow and lowered 
partial oxygen pressure (pO2) in the 
tumors are consequences of the applied 
electric pulses (32). The reduced pO2 can 
activate bioreductive drugs to exhibit a 
cytotoxic effect on hypoxic cells (33). In 
well- oxygenated cells, the drug remains 
inactive. On the other hand, tumor hypoxia 
induced by application of electric pulses 
can improve therapeutic conditions for 
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the use of hyperthermia since tumor cells 
are more sensitive to heat in sub-optimal 
physiological conditions (34).
Electrochemotherapy is an effective 
cytoreductive treatment; however, 
its curative effect depends on the 
permeabilisation of possibly all cells in 
the tumour. Since permeabilisation of 
every single cell in the tumour is virtually 
impossible, electrochemotherapy could 
be combined with other cytoreductive 
treatments that should have a systemic 
component. This can be achieved by a 
combination of electrochemotherapy with 
electrotransfer of different therapeutic 
genes acting either locally or sistemically, 
such as p53, IL-2; GM-CSF or IL-12. The 
results of the studies demonstrate positive 
results, further supporting this concept 
(35-38).
Finally, electrochemotherapy with cisplatin 
or bleomycin is also successfully used 
in veterinary medicine. It was used to 
treat different tumors, such as mammary 
adenocarcinoma, fibrosarcoma, 
cutaneous mast cell tumor, hemangioma, 
hemangiosarcoma, perianal tumors, 
neurofibroma and sarcoids in dogs, 
cats, hamsters, rabbits and horses. 
Recent reports demonstrated successful 
treatment of different neoplasms in 
companion animals and sarcoids in horses 
either of electrochemotherapy alone or 
in combination with other treatment, 
mainly surgery (39-47). Hopefully, 
electrochemotherapy will be broadly used 
in veterinary medicine for the treatment 
of different malignancies, both in primary 
and metastatic disease.
In conclusion, electroporation in 
electrochemotherapy has already been 
very well exploited; however, there are new 
biomedical applications of electroporation 
in cancer treatment that still need testing 
and development.
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Cutaneous metastases  are fairly frequent 
manifestation of advanced malignant 
disease, comprising  about  0.7-9% of all 
cancer patients. The cutaneous 
metastases may present itself as a isolated 
disesase or may present itself as a part of 
multiple organ spread. Treatment of 
cutaneous metastases could reduce or 
eliminate  symptoms  and improve quality 
of life. There are various sorts of local 
therapies and among them 
electrochemotherapy is  gaining in 
importance. The first clinical report of 
electrochemotherapy for cutaneous 
metastases came in 1991 which reported 
good clinical results in treatment of head 
and neck tumors.  The cumulative results 
of all studies till 2006 established that 
there has been 642 cutanoeus melanoma 
metastases  treated with a complete 
response of 67%  and an objective 
repsonse of 85%. The results of the first 
multicentic  study were published the 
same year showing  that an objective 
response in 85% of treated metastases , 
regardless of tumor histology,  drug used 
or route of drug administration. With this 
multicenter study the Standard Operating 
Procedures for electrochemotherapy were 
established.  Today electrochemotherapy 
is a feasible and desirable treatment 
option for cutaneous metastases  of 
different malignant histologies.  It is more 
effective in cutaneous metastases smaller 
than 3 cm. The side effects and adverse 
events of electrochemotherapy  are 
minimal, with pain being the most frequent. 
Its advantages over other local treatments 
are that it can be used in heavily pretreated 
patients, may be repeated several times 
and usualy does not produce the ulceration 
of treated lesion.
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HOW TO TREAT CUTANEOUS TUMORS, NEW SOP AND 
SIDE EFFECTS
Julie Gehl
University of Copenhagen, Copenhagen, Denmark
By far the greatest body of 
evidence avialable in clinical use of 
electrochemotherapy stems from the 
treatment of cutaneous tumors, primarily 
metastases but also primary tumors. This 
means that experience is widespread, 
and data are available. At the same 
time the experience from treatment of 
cutaneous tumors may guide the use 
of electrochemotherapy for tumors in 
internal organs as well. After initial studies 
published in the 90’ies using custom-made 
electrodes, an important pan-European 
effort led not only to the publication of the 
ESOPE study (1), but also to manufacturing 
of equipment for clinical use (generator 
and electrodes) and to standard operating 
procedures (2). This was important in 
allowing electrochemotherapy to become 
an available treatment in many European 
countries. Numerous studies have now 
been published describing treatment results 
across tumor histologies, or specifically 
dealing with e.g. breast cancer metastases 
(3, 4), malignant melanoma metastases (5, 
6), basal cell primary carcinomas (7). In 
2013 the National Institute for Health and 
Care Excellence (NICE), UK, described 
electrochemotherapy as efficient and 
without major safety concerns (8, 9). At the 
same time continuous monitoring of side 
effects and treatment efficacy through 
databases such as the International 
Network for Sharing Practices (InspECT) 
database was encouraged.
Updated standard operating procedures 
taking into account the first 10 years of 
experience after the initial publication 
of Standard Operating Procedures have 
been published (10). Briefly, cutaneous 
tumors maybe treated either under local 
anesthesia (small, few tumors), or under 
general anesthesia (many and/or larger 
tumors), electrochemotherapy may be 
given as local injection (small, few tumors), 
or as systemic infusion (many and/or larger 
tumors). All solid tumor histologies may be 
treated with electrochemotherapy. Most 
cases need to be treated only once, and 
the response rate is high across tumor 
histologies.
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According to the standard operating 
procedure for electrochemotherapy (ECT), 
a bleomycin dose of 15 000 IU/m2 body 
surface area should be injected 
intravenously and, after an interval of 8 
minutes, electric pulses are delivered to 
the tumor. However, most of the patients 
treated with electrochemotherapy are 
older than 65 years, with the age-
dependent body changes resulting in a 
decrease lean body mass and total body 
water. Consequently, the distribution of 
water-soluble drugs, such as bleomycin, 
is reduced and higher plasma or serum 
levels of the drugs that is more than 
expected might be achieved.
On the basis of the pharmacokinetics of 
bleomycin in the elderly patients, which 
was analyzed by using a newly developed 
analytical method for determination of 
bleomycin in serum samples, a lower 
dose of bleomycin of 10 000 IU/m2 was 
recommended. Recently published clinical 
studies confirm that ECT performed with 
reduced dose of bleomycin could be as 
effective as currently recommended dose. 
Especially older patients, patients with 
impaired renal function and candidates for 
multiple ECT cycles could have the benefit 
from reduced dose protocol. 
Recently, a study on animal models, 
based on the comparison of the 
carcinoma and melanoma models, 
implicate the differences in bleomycin 
pharmacokinetics in various histological 
types of malignant tumors as a possible 
explanation of differences in response 
rates to ECT. Alterations in bleomycin 
pharmacokinetics in histologically different 
tumors could be due to variations in tumor 
vascularization, which has an impact 
on bleomycin accumulation at the time 
of electroporation. According to these 
findings, tumor vascularization might be 
used as a predictive factor for the tumor 
response to ECT.
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Due to its propensity to recur on the skin, 
melanoma represents a leading indication 
to electrochemotherapy (ECT). With the 
advent of targeted and immune therapies, 
prolonged survival is being achieved and 
new patterns of disease have emerged. 
Thus, ECT is increasingly applied not only 
as a palliative, but also as a complementary 
therapy, to enhance the care of patients 
with superficially metastatic melanoma 
through precise tumor targeting 
and prolonged locoregional control. 
Historically, several ECT studies included 
patients with melanoma, and since 2006 
ESOPE guidelines nine case series have 
been published. Complete response (CR) 
rate ranged between 20% and 50%. 
In well-selected cases, ECT allowed to 
managing metastases in challenging 
anatomical locations such as the face, oral 
cavity, and perianal region. Interestingly, 
ECT can be combined with surgery, with 
either a neoadjuvant or adjuvant intent, 
and the 2018 ESOPE guidelines include 
the option of performing debulking surgery 
and ECT within the same procedure. 
Patient-reported outcomes have been 
previously investigated in 36 patients 
by means of a dedicated questionnaire. 
In the short-term, 34 of them reported 
a positive impact on wound healing, 
bleeding, aesthetic impairment, activities 
of daily living, social relations, or pain. 
These findings have been subsequently 
confirmed in 211 melanoma patients 
by the EORTC QLQ-C30 questionnaire. 
Cutaneous and subcutaneous metastases 
from melanoma often occur in the setting 
of metastatic, disseminated disease 
and are often associated with clinical 
complications, including bleeding, pain 
and ulceration, and with resulting quality of 
life deterioration. Although a locoregional 
approach for a solitary lesion can be 
indicated, the primary aim of treatment 
in advanced cases is palliative, but can 
nonetheless include various combination/
sequencing of locoregional treatments 
(surgery, isolated limb perfusion/infusion, 
radiotherapy, T-VEC oncovirotherapy, 
ECT), and systemic therapies (immuno-, 
targeted-therapy).
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Abstract: Electrochemotherapy (ECT) of head and neck cancer can be particularly tricky because 
the Otolaryngologist has to be able to manage many different pathological conditions: small or 
large cutaneous nodules located on the skin of the upper or lower face; subcutaneous or deep 
seated tumors in proximity of vital structures and small or large mucosal lesions of the oral cavity 
or the oropharynx. Each of these situations requires specific treatment modalities ranging from 
procedures that can be conducted under local anesthesia with the use of the standard fixed-
geometry electrodes, to procedures that require general anesthesia, prophylactic tracheotomy 
and electroporation with the variable geometry.
The success of ECT in the head and neck area is strictly related to the capability of complete 
electroporation of the tumor nodules. The higher percentages of objective response are obtained 
in the skin areas, where the possibilities of complete coverage of the tumor mass is easier; while 
areas that cannot be easily exposed and reached with the electrodes, such as the oropharynx, 
or deep seated tumors show lower but still encouraging percentages of objective response. 
The development of new electrodes and the improvement of the procedures will increase the 
effectiveness of ECT in these peculiar conditions.
  
CURRENT PERSPECTIVES
Electrochemotherapy (ECT) is currently 
reserved to the palliative local treatment 
of cutaneous, subcutaneous or deep 
seated tumors of any kind of histology nor 
suitable to for standard treatments, the 
pain relief of tumor masses or the control 
of bleeding lesions (1). These pathological 
conditions can be particularly devastating 
in the head and neck area, where the 
standard treatments employed can add 
disabilities and worsen the residual quality 
of life in these patients (2).
Previous studies have proven the 
effectiveness of ECT in melanoma 
and non-melanoma skin cancers, with 
percentages of objective response verging 
100% in basal cell carcinomas (BCC) and 
with healing of the treated lesions without 
damage of the surrounding tissues and 
minimal or nil impact on the aesthetic and 
function of the head and neck subsites (3).
The treatment of the oral and oropharyngeal 
lesions is more complex and depends on 
the capability to cover with the electric field 
all the tumoral bed. Thus, small lesions 
located in easily attainable areas such as 
oral cheek, floor of the mouth, internal lip, 
mobile tongue can be successfully treated 
with standard or finger electrodes; while 
larger nodules with complex tridimensional 
growth or located in the tongue base or 
oropharynx cannot be totally covered with 
the fixed geometry electrodes (2).
Despite these technical difficulties the 
percentages of objective response are 
encouraging (56% in the EURECA study) 
(4) and will be further improved with the 
development of new electrodes capable to 
completely electroporate tumors located 
in these particular areas or with the use 
of the single electrodes and the variable 
geometry (2).
The application of the variable geometry is 
particularly indicated for the treatment of 
head and neck deep seated tumors. These 
lesions are not simply hidden under the 
mucosal or skin visible surface, but they 
can be also located near vital structures 
(large blood vessels, cranial nerves), 
bone structures or in limited spaces. The 
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determination of the adequate position for 
each single electrode and the sequence of 
the electric pulses deliverance during the 
procedure can be planned with specific 
softwares and Navigation Systems (5).
TREATMENT MODALITIES
Even if ECT in head and neck can be 
applied to the treatment of any kind of 
tumor site (cutaneous, subcutaneous, 
mucosal or deep seated) the choice of 
drug delivery, type of anesthesia and type 
of electrodes depend on the number, size, 
location and patient’s general condition 
(Table 1) (2). 
In general, when the tumors are located in 
the upper face or scalp, and are few (< 3 cm 
)and less than 2 cm in size, the procedure 
can be conducted under local anesthesia, 
both drugs (bleomycin or cisplatin) can be 
used according to the Standard Operating 
Procedures (SOP) (1), and the choice of 
the electrode depending on the nodules’ 
morphology and thickness or depth of 
invasion; while in case of more than 3 
nodules and larger than 2 cm it is better 
to proceed under general anesthesia and 
with bleomycin given intravenously.
In case of tumors located in the lower 
face or neck, intraoral or deep seated 
the procedure must be performed 
under general anesthesia because 
of the possibility of severe pain and 
muscle contractions; the  choice of drug 
administration and type of electrodes 
follow the SOPs (1).
Moreover, in case of intraoral or 
oropharyngeal lesions, a profilactic 
Figure 1 Primary BCC (left) and the response 6 months after 2 cycles of ECT (right)
Figure 2 Primary SCC (left) and the response 2 months after ECT (right)
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tracheotomy has to be considered due to 
the risk of swelling of the soft tissues.
CONTRAINDICATIONS
Contraindications to ECT in head and 
neck are the same of the SOPs (1) with 
the adjunct of macroscopic infiltration of 
the internal jugular vein or carotid artery 
because of the risk of blowout secondary 
to tumor necrosis induced by ECT (Table 
2). 
Moreover, attention must be paid in the 
treatment of full-thickness lesions of the 
cheek or peristomal recurrences because 
of the risk of salivary fistulas, or in the 
treatment of full-thickness lesions of the 
lip for the risk of labial incompetence (2,6). 
FUTURE PERSPECTIVES
Usually, ECT is a safe treatment in head 
Table 2 Absolute and relative contraindication for ECT in the head and neck area
Clinical situation Absolute contraindication Relative contraindication
Major vessel tumor infiltration Macroscopic infiltration of the 
walls of the internal jugular vein 
or carotid artery
Difficulties with local/general 
anesthesia
Yes
Allergy to bleomycin or cisplatin Yes
Cumulative dose of bleomycin >240,000 IU/m2
Full-thickness lesions of the chin, 
cheek, or lip,
Peristomal lesions
High risk of salivary fistula and/or 
labial incompetence
Cardiac arrhythmias, pacemaker Thorax application <7 cm Head neck application
(>30 cm from heart)
Pulmonary function (Fibrosis) Bleomycin i.v. <30 % O2 delivery
Bleomycin i.t.
Hematology
(PLT <70,000/mm3, INR >1,5)





Table 1 Treatment modalities for cancers of the head and neck area
Treatment Site, Number, Size Anesthesia Drug administration Electrode
Modality A Head, face
< 3 nodules
< 2 cm




Hexagonal, Finger (if 
deep
Modality B Head, face
> 3 nodules
> 2 cm
General Bleomycin i.v. Row needle, 
Hexagonal











and neck cancer patients because it 
results in minimal or null aesthetic  and 
functional compromise and leads to 
healing of treated tumor lesions without 
damage to the surrounding healthy 
tissues. Therefore, particular attention 
must be reserved to elderly patients 
because the risk of severe side effects and 
necrosis can be higher due to increased 
serum levels of bleomycin, induced by the 
reduction of total body water and a decline 
in glomerular filtration rate (7). In order to 
avoid these possible complications, some 
authors have already proposed a reduced 
dose of bleomycin (10.000 IU/m2) in elderly 
patients, instead of the standard dose of 
15.000 IU/m2, since the serum clearance 
curve of bleomycin is slower (less than 
500 ml/min) in elderly population (7).
The effectiveness of ECT in the treatment 
of cutaneous and subcutaneous tumor 
nodules, is high, with reported percentages 
of objective response approaching 100% 
(3); for this reason a future role for ECT 
as a first-line treatment of head and neck 
cancer, particularly in elderly patients, 
or as neo-adjuvant treatment for those 
cases in which surgical procedures and/or 
radiotherapy would be too devastating in 
achieving proper oncological results can 
be considered, even if randomized clinical 
trials are still necessary to confirm this 
possibility. 
Although ECT is highly efficient on treated 
nodules, it remains a local treatment 
having no apparent antitumor effects 
on non-treated distant nodules, even 
though it has been demonstrated that 
electroporation induces inflammation of 
the treated tissue and then activation of 
the immune system (8).
The combination of ECT and 
immunotherapy may have a long-term 
effect on local and systemic cancer 
eradication and seems to be a future 
perspective (9,10).
Similarly, anti-programmed cell death 
protein 1 (PD1) antibodies are also of 
great interest as they prevent the inhibitory 
effect on T cell functions of the interaction 
between PD1 (on T cells) and PD1 ligand 
(on tumor cells). Thus, a combination of 
ECT with anti-PD1 antibodies could be an 
elegant way to destroy the initial nodule 
while raising efficient antitumor responses 
to ultimately eliminate remaining and 
circulating cancer cells (8).
Alternatively, immune stimulation through 
electrogenetherapy (EGT) has also raised 
great hope for the treatment of cancer. 
Sersa et al. recently proposed a model 
of combination of ECT with peritumoral 
IL-12 electrotransfer; ECT boosted with 
immunogene electrotransfer could be 
considered a sort of in situ vaccination 
to potentiate not only death of the ECT-
treated tumor nodule but also to activate 
the immune system toward the same 
tumor cells on distant metastases where 
it can exert its immunological actions (11).
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ECT is a local treatment that combines 
application of electric pulses to increase 
the uptake of cytotoxic drugs, such as 
bleomycin and cisplatin, into tumor cells. 
ECT has already been implemented as 
palliative treatment of skin melanoma 
metastases, but is also effective in 
treatment of other cutaneous and 
subcutaneous nodules regardless of their 
histological origin. The objective response 
rate of the ECT treated nodules is 80% 
and long lasting complete response rate is 
70%. ECT was succesfully translated into 
treatment of bigger (≥ 3 cm in diameter) 
and deep-seated tumors with the 
technological adaptation of the procedure 
and verification of its safety and 
effectiveness.
Our first study on a case of patient with 
solitary colorectal cancer metastasis 
in the liver showed the feasibility of 
the method. Based on that data, first 
pilot clinical study for the treatment of 
colorectal liver metastases in order to 
evaluate the feasibility, safety and efficacy 
of electrochemotherapy was conducted. 
Treatment with electrochemotherapy was 
effective, a high response rate of complete 
response was observed. High response 
rate was observed in all groups regardless 
of anatomical locations of the liver, also on 
metastases in the vicinity of major hepatic 
vessels
Treatment of colorectal liver metastases 
with electrochemotherapy is feasible, as 
long as the electrodes are precisely placed 
into and around the metastases. Treatment 
plan should be prepared for each patient 
separately to fulfill this requirement. 
Furthermore, electrochemotherapy is 
also appropriate for the treatment of 
unresectable metastases, such as those  
located near major vessels or nerve 
bundles. Efficacy of radiofrequency 
ablation, for example, which is also one of 
the methods for treatment of inoperable 
metastases, is in the vicinity of big vessels 
lower due to heat sink effect.
Electrochemotherapy of hepatocellular 
carcinoma proved to be a feasible, safe 
and effective treatment in patients who 
were not amenable to other therapeutic 
ablative techniques. Electrochemotherapy 
is predominantly applicable in patients 
with impaired liver function due to liver 
cirrhosis and/or with lesions where a high-
risk operation is needed to achieve curative 
treatment, given the intra/perioperative 
risk for high morbidity and mortality
Finally, benefits of electrochemotherapy 
are not only due to the treatment alone, but 
survival time could be prolonged also due 
to possibility of additional treatments. Our 
ongoing study will gain new knowledge in 
a field of electrochemotherapy treatment 
of colorectal metastases.
Electrochemotherapy is safe and effective 
intraoperative treatment approach for 
liver metastases, as well as primary liver 
tumors, which are found to be in difficult-
to-treat locations or are untreatable with 
other standard ablation techniques. 
Electrochemotherapy has being translated 
also into treatment of other deep seated 
tumors. Based on the principle of 
treatment of liver tumors some studies 
performed on pancreatic tumors as well 
as bone metastases. Endoscopic devices 
suitable for treatment of colorectal tumors 
were developed as well and clinical study 
is ongoing.
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Electroporation is a phenomenon in which 
exposure of cells to short pulses of electric 
fields causes an increase in the 
permeability of the cellular membrane to 
ions, small, and large molecules (1). 
Currently, the two applications, which 
have the most clinical evidence and have 
been most intensely studied are 
electrochemotherapy (ECT) and 
irreversible electroporation (IRE) (2,3). For 
ECT the electric field pulses needed to 
achieve therapeutic effect are 8 pulses of 
100 microseconds, while for IRE, 90 
pulses of 70 to 100 microseconds are 
recommended.
The most important predictor of successful 
electroporation is the local electric field 
strength in situ (4). The electric field in 
tissue depends on the voltage applied to 
the electrodes, the number, geometry and 
position of the electrodes, and the tissue 
conductivity. The tissue conductivity of 
different tissues is markedly different, 
tumour tissue also typically has much 
higher conductivity than surrounding 
healthy tissue (5); tissue conductivity also 
transiently increases due to electroporation 
during the pulses (6). To realize patient-
specific treatment planning the following 
steps are needed: tomographic image 
segmentation, electric field calculation 
and optimization of electrode positions 
and applied voltages (7). The final results 
of the optimization need to be presented 
in an understandable way, so that the 
patient-specific treatment plan can be 
successfully followed by the performing 
physician; this can also be achieved using 
navigation systems (8).
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Ablative techniques provide an effective 
tool for local treatment of liver tumors. 
Radiofrequency ablation is the most 
frequently used local method, whereas 
electroporation-based treatments are 
being explored as possible alternatives. 
US imaging is mostly used for the 
identification of the electrode placement 
according to the treatment plan and US 
specific changes are detected for 
identification of adequate tumor coverage. 
Treatment monitoring and understanding 
the imaging findings to predict the tumor 
response to ECT are important.
The effect after ECT is slow. We observed 
tumor response in three phases after ECT: 
Immediate effects, Intermediate effects 
after a few days and late effects. 
We observed immediate effects with US, 
the changes in the ablation zone were 
followed to identify whether they appear 
in the entire treated tumor, therefore 
indicating an effective electroporation of 
the tumor. 
Intermediate and late effects can be 
evaluated with US, CT or MRI.
Morphologic methods such as the 
Response Evaluation Criteria in Solid 
Tumors (RECIST 1.1) are considered the 
gold standard for response assessment 
in the management of cancer. However 
conventional morphologic methods 
are confronting limitations in response 
assessment (1). 
All local treatments attempt to induce 
necrosis of the tumor, which may delay 
tumor shrinkage during the early post-
treatment period. Given these limitations 
of morphologic response criteria, the 
American Association for the Study of 
Liver Disease (AASLD) proposed the 
modified RECIST (mRECIST) criteria, 
which conceptualized viable tumor 
measurements (2). mRECIST had better 
overall response rate than conventional 
morphologic criteria such as RECIST 1.1 
(3) and a better correlation with survival. 
Diffusion-weighted MRI (DWI) is unique 
among imaging technique, although many 
studies have confirmed the usefulness 
of DWI and its diagnostic role in cancer 
imaging. A significant and growing volume 
of data are now gathering to support its 
use for tumour response assessment 
(4). Restriction in the diffusion of water 
molecules is directly proportional to 
the degree of cellularity of the tissue. 
In general, an increase in ADC value in 
response to treatment has been shown to 
be associated with better outcome (5,6).
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More than 30 % of patients with colorectal 
cancer developed liver metastases. 
Radical surgical resection of liver 
metastases remains the only chance of 
cure with more than 50% 5-year survival. 
Unfortunately, most of the patients are 
presented with unresectable metastases 
because of their size, number, location or 
inadequate liver remnant after resection. 
In unresectable disease, many ablative 
approaches can be used. The most 
frequent is radiofrequency ablation(RFA). 
However, RFA is less effective in the 
treatment of metastases in the vicinity of 
major hepatic vessels due to heat sink 
effect. 
From 2009 to 2018 35 patients with 
colorectal liver metastases were 
treated with electrochemoterapy at 
our department. In our first published 
analyses, 29 metastases in 16 patients 
were treated with electrochemoterapy 
during open surgery by US-guided 
insertion of long needle electrodes (with 
variable or fixed geometry) into and 
around the tumor. Up to three metastases 
not exceeding 3 cm in the diameter were 
treated with electrochemoterapy. Patients 
were divided into three groups. In the 
first two groups were patients with two-
stage liver surgery. In the first operation, 
some of the metastases were treated 
by electrochemoterapy and removed 
during the second operations. In the 
third group patients with unresectable 
metachronous metastases were treated 
with electrochemoterapy as the only 
treatment option. 
There was no perioperative mortality. 
Three patients required reoperation after 
electrochemoterapy; two because of 
colon perforation and one because of 
obstruction of small bowel because of 
adhesions. None of these complications 
were related to electrochemoterapy. 
During or after electrochemoterapy no 
major heart rhythm changes or myocardial 
ischemia were found. 
Radiological complete response was 
observed in 85% of treated metastases 
and partial in 15% after the first 
radiological evaluation. At the second 
evaluation, at a median of 147 days after 
electrochemoterapy, 71% of metastases 
were still in complete response. Response 
to electrochemoterapy was the same in 
metastases located close to major hepatic 
vessels and metastases away from the 
vessels. On pathological analysis, non 
treated metastases had a significantly 
higher percentage of residual viable tumor 
compared to electrochemoterapy treated. 
We found regressive changes in the whole 
electrochemoterapy-treated area of the 
liver with disruption of vessels less than 
5 mm in diameter and preservation of the 
larger vessels and biliary ducts. 
Electrochemoterapy of liver metastases 
is feasible, efficient and safe treatment 
modality, especially for the metastases in 
the vicinity of major hepatic vessels.
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Abstract: Electrochemotherapy provides non-thermal ablation of cutaneous as well as deep 
seated tumors. Based on positive results of the treatment of colorectal liver metastases, we 
conducted a prospective pilot study on hepatocellular carcinomas with the aim of testing 
the feasibility, safety and effectiveness of electrochemotherapy. Electrochemotherapy with 
bleomycin was performed on 17 hepatocellular carcinomas in 10 patients using a previously 
established protocol. The procedure was performed during open surgery and the patients were 
followed for median 30 months. Electrochemotherapy was feasible for all 17 lesions, and no 
treatment-related adverse events or major post-operative complications were observed. The 
median size of the treated lesions was 24 mm (range 8-41 mm), located either centrally, i.e., near 
the major hepatic vessels, or peripherally. At last radiological follow-up the complete response 
rate was 90% per patient (9/10) and 94% per treated lesion (16/17). Electrochemotherapy of 
hepatocellular carcinoma proved to be a feasible and safe treatment in all 10 patients included 
in this study. To evaluate the effectiveness of this method, longer observation period is needed; 
however, the results at medium observation time of 30 months after treatment are encouraging, 
in 16 out of 17 lesions complete response was obtained. Electrochemotherapy is predominantly 
applicable in patients with impaired liver function due to liver cirrhosis and/or with lesions where 
a high-risk operation is needed to achieve curative intent, given the intra/perioperative risk for 
high morbidity and mortality.
INTRODUCTION
Hepatocellular carcinoma (HCC), together 
with intrahepatic cholangiocarcinoma, 
represents more than 98.5% of all primary 
liver tumors, and its incidence is rising 
worldwide. HCC is the third most common 
cause of cancer-related deaths in the 
world and is responsible for between 
650,000 and one million deaths globally 
per year (1-3).
The optimal treatment options for 
patients with HCC are curative surgical 
resection, liver transplantation and, in rare 
cases, radio-frequency ablation (RFA). 
Other methods, such as local ablative 
techniques (percutaneous ethanol (PEI) or 
acetic acid injection (PAI) in tumor, RFA, 
microwave ablation (MWA), transarterial 
chemoembolization (TACE), targeted 
therapy, chemo- and radiotherapy 
and others are used only as palliative 
treatment and in some cases as bridging 
therapy (TACE, RFA) for possible curative 
liver transplantation. Most patients with 
HCC are complex, with only 20% having 
straight forward treatment scenarios. 
Therefore, the majority of patients (more 
than 60%) receive some combination of 
therapies, depending on the stage of the 
disease (4-10).
Despite intensive surveillance programs, 
considerable recent therapeutic advances, 
and the use of potentially radical 
treatments, prognosis and life expectancy 
remain low in patients with HCC (11). 
Electroporation-based treatments, 
including irreversible electroporation (IRE) 
and electrochemotherapy, are new local 
treatment approaches that are gaining 
importance. Electrochemotherapy already 
has an established place among other 
local treatments for the treatment of 
cutaneous tumors (12), but the translation 
of electrochemotherapy into deep-seeded 
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tumors is lagging behind (13).
However, the first encouraging results for 
the treatment of colorectal liver metastases 
have already been published (14,15). 
Based on the encouraging clinical results, 
we conducted a prospective pilot clinical 
study to establish the feasibility, safety, 
and effectiveness of electrochemotherapy 
in the treatment of HCC. In the study, 
patients not amenable to other therapeutic 
ablative techniques were included. 
Furthermore, electrochemotherapy was 
also employed to treat tumors located 
in the vicinity of the major blood vessels 
where other ablative techniques, such 
as RFA or MWA, would not have been 
efficient due to the heat sink effect.
PATIENTS AND METHODS
Study design
The study was designed as a prospective, 
pilot study. Patients were presented 
at the multidisciplinary team meetings 
consisting of a surgeon, radiologist 
and gastro-oncologist. Before inclusion 
into the trial, all patients signed written 
informed consent. The primary endpoint 
of the study was to assess the feasibility 
and safety of electrochemotherapy in the 
treatment of HCC. The secondary aim was 
to determine the efficacy of ECT, based on 
a radiological evaluation of treated lesions, 
as measured by modified Choi criteria 
(17). Electrochemotherapy was performed 
according to the Standard Operating 
Procedures for treatment of cutaneous 
tumors and the associated modifications 
for the treatment of liver tumors and 
reporting of data according the published 
recommendations (15,18,19).
Patients
In this trial, 10 patients with 17 lesions were 
enrolled from February 2014 to November 
2016, based on the inclusion and 
exclusion criteria (Table 1). The diagnosis 
was confirmed either histologically (in 4 
patients) (20), or by typical radiological 
appearance according to the EASL-
EORTC Clinical Practice Guidelines for 
Management of hepatocellular carcinoma 
(5). Patients were divided into three groups 
according to the indications and previous 
treatments.
The first group represented patients 
in whom the local ablative technique 
was unsuccessful (TACE/RFA) and 
electrochemotherapy was offered as 
an additional treatment. In this group, 
3 patients with 6 lesions were treated. 
Two of these patients underwent TACE, 
which was unsuccessful (progress of the 
treated lesion at the follow up), and further 
treatment with TACE was not indicated. 
According to the Barcelona Clinic Liver 
Cancer (BCLC) algorithm (21), treatment 
for advanced or terminal stage disease 
should be offered. The third patient in this 
group had previously been treated with 
RFA, which was unsuccessful, and other 
ablative techniques were not indicated.
The second group included patients for 
whom transplantation, radical surgery 
or other local ablative techniques 
were not indicated due to patients' 
performance status, the location of 
the lesions, or contraindications to 
the ablative techniques. However, 
electrochemotherapy was performed with 
curative intent. In this group, 6 patients 
with 9 lesions were treated.
The third group included a patient for 
whom electrochemotherapy was offered 
as “bridging” to transplantation option. 
In this patient, 2 lesions were treated. 
During the first procedure in 2009, right 
hemihepatectomy with resection of middle 
and right hepatic veins in un-cirrhotic liver 
was performed due to HCC. In 2015, the 
patient developed 2 new HCC lesions 
located in proximity to the left hepatic 
vein, so electrochemotherapy was offered 
to the patient as a “bridging” to liver 
transplantation.
Lesions were defined as “central” or 
“peripheral” based on their relation to the 
major blood vessels. The term “central” 
was used for the lesions in the close vicinity 
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of the major blood vessels including 
the main hepatic or portal veins and the 
main hepatic arterial branches. The term 
“peripheral” was used for lesions not 
adjacent to the major blood vessels where 
RFA or other ablative techniques were 
not indicated by interventional radiologist 
blinded to the study (22,23). 
Treatment procedure
All 10 patients enrolled in the study were 
treated during open surgery. Median 
laparotomy, extended to the right 
subcostal incision, was performed in 8/10 
patients. In 2 patients, only upper median 
laparotomy was used. The electrodes 
used for electric pulse delivery were either 
single long (20 cm) needle electrodes 
(variable geometry) with 3 or 4 cm active 
part or 7-needle electrodes fixed on the 
holder in hexagonal geometry and 3 cm 
active part (24,25). The choice of electrode 
use was dependent on the location of the 
lesion. Electrodes with variable geometry 
i.e., long needle electrodes were used for 
deep seated tumors located more than 
3 cm below the surface of the liver. The 
hexagonal electrodes were used for more 
superficial tumors that had their deepest 
margins less than 3 cm from the liver 
surface (24,25). Specifically, the treatment 
of lesions in segment 8 included the use of 
both types of the electrodes, where for the 
use of hexagonal electrodes mobilization 
of the liver was required. The intraoperative 
ultrasound was used to identify lesions 
and aid the positioning of the electrodes 
into and around the tumor. The long needle 
electrodes were positioned according to 
the pretreatment plan prepared for each 
patient and specific tumor individually 
using previously developed procedures 
(26,27). Plans were developed based on 
computed tomography and/or magnetic 
resonance scans taken less than 30 
days prior to treatment. Target lesions 
(up to 41 mm in the largest diameter) 
were segmented. A gradient-based 
optimization algorithm was used to 
optimize voltage between each electrode 
pair to maximize tumor coverage above 
the reversible electroporation threshold 
(400 V/cm) and minimize the volume 
of healthy liver parenchyma above the 
irreversible electroporation threshold 
(700 V/cm). The intravenous bolus of 
bleomycin was given to the patient after 
the intra-operative ultrasound confirmed 
the correct electrode placement. Trains 
of eight electric pulses (electrodes with 
variable geometry) or 24 (fixed geometry) 
electric pulses (each pulse 100 ms long) 
were delivered to each pair of electrodes 
consecutively. Electric pulses were 
delivered by electric pulse generator 
during an interval of 8-28 min after the 
intravenous injection of bleomycin 15,000 
IU/m2 in bolus, as being determined to be 
the optimal pharmacological peak for the 
bleomycin in the tumors (16).
Efficacy assessment based on radiology
Lesions treated in the study were assessed 
before electrochemotherapy by contrast-
enhanced computed tomography (CECT) 
or with magnetic resonance imaging 
(CEMRI) using a distinct hepatocyte 
contrast (gadoliniumethoxybenzyl-
diethylenetriaminepentaacetic acid-Gd-
EOB-DTPA). The follow-up was performed 
by CECT in all the patients but one in whom 
the CEMRI was performed at the 3- months 
follow-up. Images were evaluated by two 
radiologists, one of whom was blinded to 
the trial. Modified Choi criteria were used 
to assess the treatment response (17). 
Evaluations of both radiologists were in 
complete consensus.
RESULTS
Feasibility, safety, and response to 
treatment evaluation were evaluated for 
all 10 patients and 17 lesions.
Feasibility
Electrochemotherapy was feasible in all 10 
patients enrolled in the study, according 
to the inclusion and exclusion criteria 
(Table 1). Three females and 7 males were 
included, with a median age 69.5 years 
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(range: 57-78 years). Three patients had 
undergone previous treatment with TACE 
and/or RFA, and one had undergone 
liver resection. Six patients had received 
electrochemotherapy as a primary 
treatment. The previously operated patient 
had electrochemotherapy as a bridging 
procedure for liver transplantation.
Patients were treated according to the 
Standard Operating Procedures for 
cutaneous tumors, modified for the liver 
tumors during open surgery (16,24). 
The median size of the treated lesions 
was 24 mm with a range of 8-41 mm. 
Electrochemotherapy was also feasible in 
patients with centrally located lesions in 
the vicinity of major hepatic vessels (8/17 
lesions).
Safety
Adverse reactions related to electro-
chemotherapy did not occur, despite the 
American Society of Anesthesiologists 
(ASA) score of 3 (8/10 patients) and ASA 
score of 2 (2/10 patients). No intraoperative 
or postoperative complications during 
the first 24 h occurred. The exceptions 
were the two patients with the ascites 
production after the procedure due to 
transient liver failure. Ascites was resolved 
by conservative measures. Nevertheless, 
patients were classified as Clavien-Dindo 
3a and 3b because in both additional 
diagnostic/intervention was necessary: in 
one patient the ERCP was performed due 
to choledocholithiasis; the second patient 
had elevation of cholestatic enzymes and 
the endoscopic ultrasound was performed 
to clarify the origin of elevated enzymes. 
The impaired liver function was a result of 
liver cirrhosis before the operation and was 
not related to the electrochemotherapy.
All 10 patients were discharged from the 
hospital after a median hospitalization 
of 5.5 days (range: 2-20 days) and were 
followed on an outpatient basis. ECG 
signals were recorded during and 24 h 
after the electrochemotherapy. No onset of 
new or worsening of existing pathological 
morphological changes was recorded. 
There were no signs of myocardial 
ischemia, new-onset of atrial and/or 
ventricular extrasystoles, or increased 
frequency of abnormal heartbeats in 
Table 1 Inclusion and exclusion criteria for electrochemotherapy in HCC. 
Inclusion criteria
1. HCC confirmed by radiological imaging and/or histology. 
2. Age more than 18 years.
3. Life expectancy more than 3 months.
4. Performance status Karnofsky 70 or WHO (World Health Organization) < 2.
5. Signed informed consent.
6. Unanimous decision of the multidisciplinary liver tumor team before entering the trial 
(surgeon, gastro-oncologist and radiologist).
Exclusion criteria
1. Multiple primary tumors.
2. Extrahepatic disease.
3. Poor performance status.
4. Clinically significant ascites.
5. Exposure to cumulative bleomycin doses in excess of 400 mg.
6. Allergic reaction to bleomycin.
7. Impaired kidney function (Creatinine > 150 mmol/l).
8. Pregnancy, epilepsy, heart arrhythmias or patient having cardiac pace maker.
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relation to the electrochemotherapy 
procedure. Centrally located tumor 
lesions (8/17) near major hepatic vessels 
were successfully treated without adverse 
events.
Effectiveness
The first radiologic follow-up was 1 month 
after treatment (median 31 days; range 
from 23 to 45 days). All 17 lesions were 
evaluated and a complete response was 
found in 15/17 lesions (88%). Two lesions 
had a partial response according to the 
modified Choi criteria, due to the small 
field of enhancement, without changes in 
lesion size.
The second radiological follow-up was 3-6 
months after the treatment (median 194 
days; range from 100 to 218 days). All 17 
lesions were evaluated, and according to 
the modified Choi criteria, all of the lesions 
that had been initially evaluated after 1 
month, i.e., the 15/17 lesions, remained in 
complete response. Two lesions identified 
in the previous follow-up as partial 
responses (2/17, 12%) remained in the 
stage of partial response and the patients 
were considered being in stable disease.
The last radiological follow-up was 12-
37 months after the treatment (median 
30 months). One of the lesion that was 
previously evaluated as stable disease, 
was described as complete response after 
last radiological follow-up. The rest of the 
lesions remained unchanged, therefore a 
complete response was observed in 16/17 
lesions (94%).
DISCUSSION
Electrochemotherapy has, after successful 
translation into treatment of cutaneous 
tumors, progressed into translation of 
deep seated tumors. This study confirmed 
the feasibility, safety and effectiveness 
of electrochemotherapy in the treatment 
of HCC. No treatment or postoperative 
adverse events were recorded, including 
in patients with lesions located near 
the major hepatic vessels. The overall 
response was high, 94% (16/17) of the 
treated lesions and 90% (9/10) of patients 
had complete responses.
The feasibility and safety of 
electrochemotherapy was already 
demonstrated in a previous study on the 
treatment of colorectal liver metastases. 
The response rate of that study was 85% 
complete responses on 29 metastases 
in 16 patients which is comparable to 
the 94% complete response rate in this 
prospective pilot study on HCC (15). The 
technology that has proven to be feasible 
and safe in the previous study was also 
confirmed in this study and another 
recently published study (14), in cases 
where other ablative techniques are not 
indicated.
In this study, not only patients with 
previously unsuccessfully treated tumors, 
but also patients for whom standard 
treatment with curative intent could not 
be offered were included. In one patient, 
this method was used as a bridging to 
liver transplantation. Two patients had 
post-operative complications in the form 
of transient liver function failure with 
consequent ascites production. Based on 
poor performance status of the recruited 
patients in whom other treatments 
were not feasible, electrochemotherapy 
provides effective treatment of lesions 
in such patients. Therefore, it could be 
considered as a technique with curative 
intent, which, however, needs to be 
confirmed in a phase II study in a larger 
cohort of patients.
One of the limitations of this approach 
is that larger tumors tend to have lower 
response rates. As indicated by several 
other studies, tumors larger than 3 cm 
in diameter seldom have complete 
responses (28,29). The method in our case 
was upgraded by the treatment plan that 
intended to predict the optimal electrode 
placement for effective electroporation 
of the tumors. This certainly aided 
better execution of the electroporation 
of lesions larger than 3 cm in diameter, 
but the step for effective verification of 
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the tumor coverage after electroporation 
is still missing. This can be executed 
either by US verification, as noted in IRE 
and also by electrochemotherapy, or by 
development of measuring tools for the 
current distribution in the tumors by MRI, 
which is still in progress (29-31).
This study, however, has some limitations. 
Based on the fact that it is a pilot study 
and on small cohort of patients, only ten, 
the conclusion about the effectiveness 
of electrochemotherapy is premature. 
Nevertheless, the preliminary data foster 
the continuation of this study in phase II 
one.
In conclusion, our experience 
demonstrate feasibility, safety and 
provides preliminary data on the high 
effectiveness of electrochemotherapy 
in HCC. Electrochemotherapy could be 
predominantly applicable in patients with 
impaired liver function due to liver cirrhosis 
and/or with lesions where a high-risk 
operation is needed to achieve curative 
intent.
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